- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07394790
Liikuntalääkitysohjelman tehokkuus perusterveydenhuollossa 65-vuotiailla ja sitä vanhemmilla aikuisilla: PREFIS-AP
Fyysisen harjoitusohjelman reseptiohjelman tehokkuus perusterveydenhuollossa fyysisen kunnon ja elämänlaadun parantamiseksi 65-vuotiailla ja sitä vanhemmilla aikuisilla maaseututerveysalueella: PREFIS-AP satunnaistettu kontrolloitu tutkimus
This randomized controlled trial aims to evaluate the effectiveness of an individualized Physical Exercise Prescription Program delivered in Primary Care for adults aged 65 years and older. The intervention includes a structured assessment of physical fitness, muscle function and mass, physical activity level, and quality of life, followed by a tailored exercise plan encompassing aerobic, strength, respiratory, flexibility, and balance training. Outcomes will be compared with a control group receiving standard health advice to walk briskly for at least 30 minutes daily. The study also explores associations between polypharmacy, muscle function, physical performance, and quality of life.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Sedentary behavior is strongly associated with multiple adverse health outcomes, particularly in older adults. Conventional lifestyle advice alone has shown limited effectiveness in increasing physical activity levels. Exercise prescription delivered through structured evaluation, individualized planning, and scheduled follow-up may lead to clinically significant improvements in physical function and quality of life.
This study will recruit 210 adults aged ≥65 years from a rural Primary Care center. Participants will undergo baseline assessments including sociodemographic variables, anthropometric measures, muscle strength (handgrip dynamometry and chair stand test), aerobic capacity (6-minute walk test), muscle mass (calf circumference and ultrasound of rectus femoris), physical activity level (GPAQ), and quality of life (SF-36). After randomization (1:1), the intervention group will receive a personalized exercise prescription generated through the MEDORA Primary Care electronic system and supervised by a qualified Exercise Technician. The control group will receive routine health advice.
After three months, all participants will be reassessed using the same measures. The study will analyze the effect of the intervention on physical fitness, physical activity, muscle mass and function, and quality of life, including sex-specific differences and the role of polypharmacy. The project incorporates a partial masking strategy and uses REDCap for data management and anonymization.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Víctor Manuel González Rodríguez, MD
- Puhelinnumero: 54196 +34923 356 677
- Sähköposti: vmgonzalez@saludcastillayleon.es
Opiskelupaikat
-
-
Salamanca
-
Villoría, Salamanca, Espanja, 37339
- Rekrytointi
- Centro de Salud de Villoria
-
Ottaa yhteyttä:
- Víctor Manuel González Rodríguez, MD
- Puhelinnumero: 54196 34 923 356 677
- Sähköposti: vmgonzalez@saludcastillayleon.es
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age ≥ 65 years
- Motivated to participate and able to provide informed consent
- Able to attend baseline assessment and follow-up
- Clinical stability allowing participation in exercise evaluation
Exclusion Criteria:
- Recent myocardial infarction
- Unstable angina
- Uncontrolled arrhythmias (symptomatic or hemodynamically compromising)
- Syncope
- Acute endocarditis, myocarditis, or pericarditis
- Severe or symptomatic aortic stenosis
- Uncontrolled heart failure
- Recent pulmonary thromboembolism or pulmonary infarction
- Lower-limb thrombosis
- Severe aortic stenosis or suspected dissecting aortic aneurysm
- Uncontrolled asthma
- Pulmonary edema
- Acute respiratory failure
- Acute non-cardiopulmonary illness that impairs exercise capacity (e.g., infection, thyrotoxicosis, acute renal failure)
- Mental disorder that prevents adequate cooperation.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Physical Exercise Prescription Program
Participants receive a 12-week individualized multicomponent Exercise Prescription Programme integrated into routine Primary Care and supported by the MEDORA® electronic health record. Exercise prescription is based on baseline clinical and functional assessment and includes aerobic, resistance, balance and flexibility exercise, with respiratory muscle training when considered clinically indicated. Exercise is performed both independently at home and during supervised group reinforcement sessions available three days per week in municipal sports facilities. During supervised sessions, each participant follows his or her individualized exercise prescription rather than a uniform group exercise programme. Exercise type, intensity, duration, frequency and progression are individualized according to baseline clinical and functional status, tolerance and progression. |
Participants receive a structured and individualized 12-week program including: Aerobic exercise (continuous and interval training, intensity guided by Borg scale) Strength training using elastic bands (progressively increasing repetitions, series, and load) Respiratory exercises with pressure-based devices Flexibility exercises (static stretching routines) Balance training (single-leg stance, heel-toe walking, eyes-closed tasks) The program is generated through the MEDORA electronic system after baseline evaluation. A certified Exercise Technician provides instruction, supervision, and progression adjustments. Exercise type, intensity, duration, frequency and progression are individualized within the exercise-prescription framework according to baseline clinical and functional assessment |
|
Ei väliintuloa: Standard Health Advice
Participants allocated to the control group receive usual Primary Care and general physical-activity advice consistent with World Health Organization recommendations. They do not receive an individualized structured exercise prescription, supervised reinforcement sessions, or intervention-specific follow-up. The study did not systematically prescribe control participants to walk briskly for at least 30 minutes per day. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in Quality of Life
Aikaikkuna: Baseline to 3 months.
|
Quality of Life will be measured by the SF-36 questionnaire. The SF-36 questionnaire is a widely used, patient-reported questionnaire measuring health-related quality of life. It uses points to assess health, with responses on Likert scales (e.g., 0 to 100) transformed into scores for 8 health domains: physical functioning, role limitations (physical/emotional), bodily pain, general health, vitality, social functioning, and mental health, where higher scores mean better health, ranging from 0 (maximum disability) to 100 (no disability). |
Baseline to 3 months.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Physical Activity Level (GPAQ)
Aikaikkuna: Baseline to 3 months.
|
Change in physical activity level as measured by the Global Physical Activity Questionnaire (GPAQ), including time spent in work-related activity, transport-related activity, leisure-time activity, and sedentary behavior. Participants will be classified into WHO categories (high, moderate, or low/inactive) based on standardized scoring procedures. |
Baseline to 3 months.
|
|
Aerobic Capacity (6-Minute Walk Test)
Aikaikkuna: Baseline to 3 months.
|
Change in functional aerobic capacity assessed by the 6-minute walk test (6MWT). The primary variable will be the total distance walked in meters during 6 minutes. Physiological responses (heart rate, oxygen saturation, perceived exertion using Borg scale) will also be recorded. |
Baseline to 3 months.
|
|
Muscle Strength - Handgrip Dynamometry
Aikaikkuna: Baseline to 3 months.
|
Change in maximal isometric handgrip strength measured with a JAMAR dynamometer (kg), using the highest value from standardized bilateral measurements. Cut-off values will follow European sarcopenia consensus criteria (<27 kg for men; <16 kg for women). |
Baseline to 3 months.
|
|
Muscle Strength - Chair Stand Test
Aikaikkuna: Baseline to 3 months.
|
Change in lower-limb functional strength measured by the 30-second chair stand test. The outcome is the total number of complete sit-to-stand repetitions performed within 30 seconds following standardized protocol. |
Baseline to 3 months.
|
|
Muscle Mass - Calf Circumference
Aikaikkuna: Baseline to 3 months.
|
Change in muscle mass estimated by calf circumference (cm), measured at the widest point of the calf using a flexible tape. A value <31 cm will be considered indicative of potential muscle mass deficit. |
Baseline to 3 months.
|
|
Muscle Mass - Ultrasound of Rectus Femoris
Aikaikkuna: Baseline to 3 months.
|
Change in quantitative and qualitative muscle parameters assessed by ultrasound of the rectus femoris (muscle thickness, cross-sectional area, and echogenicity), following validated measurement criteria for sarcopenia assessment. |
Baseline to 3 months.
|
|
Sex Differences in Response to the Exercise Prescription Program (Standardized Change Score)
Aikaikkuna: Baseline to 3 months.
|
This outcome will assess whether biological sex modifies the effect of the intervention on functional and health-related outcomes. Sex-specific differences will be evaluated using standardized change scores (z-scores). The standardized composite score will be derived from the following previously defined outcome measures: Muscle strength (handgrip dynamometry (kg) and the 30-second chair stand test) Aerobic capacity (6-minute walk test) Muscle mass, assessed by calf circumference (cm) and ultrasound measurements of rectus femoris muscle thickness Physical activity level, (Global Physical Activity Questionnaire (GPAQ) Health-related quality of life (SF-36 questionnaire) Each variable will be standardized before aggregation to ensure comparability across different units of measurement. The resulting composite score will be compared between men and women to determine if sex influences the magnitude of response to the exercise prescription program. |
Baseline to 3 months.
|
|
Correlation Between Polypharmacy and Change in Handgrip Strength
Aikaikkuna: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in muscle strength in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Muscle strength will be assessed by handgrip strength, measured in kilograms (kg) using a calibrated hand dynamometer. Change in handgrip strength will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Appendicular Skeletal Muscle Mass
Aikaikkuna: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in muscle mass in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Muscle mass will be assessed as appendicular skeletal muscle mass, measured in kilograms (kg) using dual-energy X-ray absorptiometry (DXA). Change in muscle mass will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Physical Performance
Aikaikkuna: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in physical performance in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Physical performance will be assessed using the Short Physical Performance Battery (SPPB), reported as a total score (points on a standardized scale). Change in SPPB score will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
|
Correlation Between Polypharmacy and Change in Quality of Life
Aikaikkuna: Baseline to 3 months
|
This outcome will assess the correlation between baseline medication burden and change in quality of life in older adults from baseline to 3 months. Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications). Quality of life will be assessed using the EuroQol-5 Dimension (EQ-5D) questionnaire, reported as a standardized index score. Change in EQ-5D score will be calculated as the difference between baseline and 3-month values. |
Baseline to 3 months
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muut tutkimustunnusnumerot
- PREFIS-AP
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.
IPD-jaon aikakehys
Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.
IPD-jaon käyttöoikeuskriteerit
Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- ANALYTIC_CODE
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .